Kiran Mazumdar-shaw

Executive Chairperson, Biocon

Search every verified Kiran Mazumdar-shaw interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. Kiran Mazumdar-Shaw, Executive Chairperson of Biocon, has been discussing the company’s growth strategy and the broader challenges facing women entrepreneurs and the Indian biotech sector. In a July 2026 interview with NDTV Profit, she stated that Biocon expects to double its business over the next five fiscals and aims to become a $20 billion company by market capitalization. She attributed this potential growth to the company’s differentiated portfolio of biosimilars, insulins, and GLP-1s, as well as its end-to-end manufacturing capabilities. In a separate conversation at the Future Female Forward event, Mazumdar-Shaw said that 50% of Biocon’s research employees are women. She also commented that women entrepreneurs face greater difficulty than men in raising capital, saying that "banks and financial institutions and venture funds are very reluctant to really invest in women." Mazumdar-Shaw has also spoken about the need for regulatory reforms in India to foster innovation. At the India Global Forum in London in June 2026, she said that "the world doesn't wait for us" and called for "very rapid regulatory reforms" to help India compete globally. She noted that India is often perceived as a generics-focused country and argued that the country needs to emulate the US ecosystem to retain intellectual property and grow company value. In a BBC StoryWorks documentary on cancer care, she stated that Biocon’s mission is to make life-saving medicines accessible through biosimilars, which she described as having the power to bridge the gap between access and affordability for patients worldwide.